Asclepios Biosearch
1
14M
1
0.08
1
- Areas of investment
Summary
Asclepios Biosearch is the famous Corporate Investor, which was founded in 2009. The main department of described Corporate Investor is located in the London. The fund was located in Europe if to be more exact in United Kingdom.
Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Genmedica Therapeutics, Genmedica Therapeutics For fund there is no match between the location of its establishment and the land of its numerous investments - Spain. Among the most successful fund investment fields, there are Pharmaceutical, Biotechnology.
The standard case for the fund is to invest in rounds with 1 partaker. Despite the Asclepios Biosearch, startups are often financed by VenturCap, Uninvest, Pont Mestres & Asociados. In the next rounds fund is usually obtained by Caixa Capital Risc.
The fund is constantly included in less than 2 deals per year. The common things for fund are deals in the range of 10 - 50 millions dollars. The important activity for fund was in 2012.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 1
- Rounds per year
- 0.08
- Investments by industry
- Medical Device (1)
- Biotechnology (1)
- Pharmaceutical (1)
- Investments by region
-
- Spain (1)
- Peak activity year
- 2012
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 17
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.